53981-38-7

Usage

Uses

Used in Organic Synthesis:
CHROMAN-4-YLAMINE is used as a building block in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and functional group make it a valuable component in the development of new and effective compounds for medical and agricultural applications.
Used in Chemical Research and Experimentation:
As a reagent, CHROMAN-4-YLAMINE is utilized in chemical research and experimentation to explore its properties and reactions. This helps scientists understand its behavior in different chemical environments and contributes to the advancement of chemical knowledge.
Used in Therapeutic Applications:
CHROMAN-4-YLAMINE has been investigated for its potential therapeutic applications in the treatment of various medical conditions, including neurodegenerative diseases. Its exploration in this area highlights the compound's potential to contribute to the development of new treatments and therapies for patients.

InChI:InChI=1/C9H11NO/c10-8-5-6-11-9-4-2-1-3-7(8)9/h1-4,8H,5-6,10H2/p+1/t8-/m0/s1

Upstream product

• 24541-01-3 chroman-4-one oxime 
• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 
• 90609-63-5 3,4-dihydro-2H-chromene-4-amine hydrochloride 
• 676133-62-3 3,4-dihydro-2H-4-chromenyl azide 
• 24541-01-3 (4E)-2,3-dihydro-4H-chromen-4-one oxime 
• 238764-07-3 tert-butyl N-(3,4-dihydro-2H-4-chromenyl)carbamate 

Downstream Products

• 81816-67-3 1-(3,4-dihydro-2H-chromen-4-yl)-4-methylpiperazine 
• 81816-66-2 1-Chroman-4-yl-4-phenyl-piperazine 
• 81816-70-8 1-Chroman-4-yl-4-(4-methoxy-phenyl)-piperazine 
• 81816-69-5 1-Chroman-4-yl-4-(3-methoxy-phenyl)-piperazine 
• 81816-68-4 1-Chroman-4-yl-4-(2-methoxy-phenyl)-piperazine 
• 81816-63-9 Bis-(2-chloro-ethyl)-chroman-4-yl-amine; hydrochloride 
• 735248-42-7 6-bromochroman-4-amine 
• 730980-58-2 2-methoxy-N-((R)-3,4-dihydro-2H-chromen-4-yl)acetamide 
• 1035093-81-2 (4S)-chroman-4-amine hydrochloride 
• 903581-19-1 N-(5-fluoro-2-(methylsulfonyl)phenyl)chroman-4-amine 
• 188198-38-1 (4S)-3,4-dihydro-2H-l-benzopyran-4-amine 
• 210488-55-4 (R)-chroman-4-ylamine 
• 1061690-83-2 C₁₆H₁₅NO₂ 
• 676133-63-4 tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-3-(3,4-dihydro-2H-chromen-4-ylamino)-2-hydroxypropylcarbamate 

Relevant academic research and scientific papers

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

MOF-derived cobalt nanoparticles catalyze a general synthesis of amines

The development of base metal catalysts for the synthesis of pharmaceutically relevant compounds remains an important goal of chemical research. Here, we report that cobalt nanoparticles encapsulated by a graphitic shell are broadly effective reductive amination catalysts. Their convenient and practical preparation entailed template assembly of cobaltdiamine- dicarboxylic acid metal organic frameworks on carbon and subsequent pyrolysis under inert atmosphere.The resulting stable and reusable catalysts were active for synthesis of primary, secondary, tertiary, and N-methylamines (more than 140 examples).The reaction couples easily accessible carbonyl compounds (aldehydes and ketones) with ammonia, amines, or nitro compounds, and molecular hydrogen under industrially viable and scalable conditions, offering cost-effective access to numerous amines, amino acid derivatives, and more complex drug targets.

Microwave-Enhanced Asymmetric Transfer Hydrogenation of N-(tert-Butylsulfinyl)imines

Microwave irradiation has considerably enhanced the efficiency of the asymmetric transfer hydrogenation of N-(tert-butylsulfinyl)imines in isopropyl alcohol catalyzed by a ruthenium complex bearing the achiral ligand 2-amino-2-methylpropan-1-ol. In addition to shortening reaction times for the transfer hydrogenation processes to only 30 min, the amounts of ruthenium catalyst and isopropyl alcohol can be considerably reduced in comparison with our previous procedure assisted by conventional heating, which diminishes the environmental impact of this new protocol. This methodology can be applied to aromatic, heteroaromatic and aliphatic N-(tert-butylsulfinyl)ketimines, leading, after desulfinylation, to the expected primary amines in excellent yields and with enantiomeric excesses of up to 96 %. Microwave irradiation promotes the asymmetric transfer hydrogenation of N-(tert-butylsulfinyl)imines in 2-propanol catalysed by a ruthenium complex bearing an achiral β-amino alcohol as ligand. After desulfinylation, α-branched primary amines containing aromatic, heteroaromatic and aliphatic substituents are obtained in excellent yields and with enantiomeric excesses of up to 96 %.

1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel triazolo [4,3-a]pyridine derivatives of Formula (I), wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.

Asymmetric synthesis of chiral primary amines by transfer hydrogenation of N -(tert -Butanesulfinyl)ketimines

(Figure presented) The diastereoselective reduction of (R)-N-(tert- butanesulfinyl)ketimines by a ruthenium-catalyzed asymmetric transfer hydrogenation process in isopropyl alcohol, followed by desulfinylation of the nitrogen atom, is an excellent method to prepare highly enantiomerically enriched α-branched primary amines (up to >99% ee) in short reaction times (1-4 h). (1S,2R)-1-Amino-2-indanol has been shown to be a very efficient ligand to perform this transformation. Ketimines bearing either an aryl or a heteroaryl group and an alkyl group as substituents of the iminic carbon atom are very good substrates for this process. The reduction of a dialkyl ketimine could also be achieved, affording the expected amine with moderate optical purity (69% ee). Some amines which are precursors of very interesting biologically and pharmacologically active compounds have been prepared in excellent yields and enantiomeric excesses.

2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors

A novel class of Janus tyrosine kinase 3 (JAK3) inhibitors based on a 2-benzimidazoylpurinone core structure is described. Through substitution of the benzimidazoyl moiety and optimization of the N-9 substituent of the purinone, compound 24 was identified incorporating a chroman-based functional group. Compound 24 shows excellent kinase activity, good oral bioavailability and demonstrates efficacy in an acute mechanistic mouse model through inhibition of interleukin-2 (IL-2) induced interferon-γ (INF-γ) production.

SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS

The invention relates to 5-HT6 receptor antagonists. Novel arylamine compounds having the formula: (see formula I) and pharmaceutically acceptable salts and/or esters thereof, wherein - n is 0, 1, 2, 3, or 4; - A, when present is a lower alkyl

Cyclic amine derivatives and methods of use

Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES

Disclosed are compounds of the formula: where variables Q, Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer’s disease and other diseases characterized by deposition of A beta peptide in a mammal.